Valuation : Cytosorbents Corporation

Market Cap 24.12M 20.82M 19.61M 17.89M 33.39M 2.29B 33.67M 232M 90.05M 1.17B 90.56M 88.59M 3.83B P/E 2026 *
-1.74x
P/E 2027 * -8.53x
Enterprise Value 24.12M 20.82M 19.61M 17.89M 33.39M 2.29B 33.67M 232M 90.05M 1.17B 90.56M 88.59M 3.83B EV / Sales 2026 *
0.62x
EV / Sales 2027 * 0.55x
Free-Float
84.28%
Yield 2026 *
-
Yield 2027 * -
1 day+13.55%
1 week+8.02%
Current month+12.55%
1 month+6.35%
3 months-17.97%
6 months-49.00%
Current year-39.96%
1 week 0.31
Extreme 0.3115
0.47
1 month 0.3
Extreme 0.3
0.47
Current year 0.3
Extreme 0.3
0.84
1 year 0.3
Extreme 0.3
1.04
3 years 0.3
Extreme 0.3
2.66
5 years 0.3
Extreme 0.3
9.66
10 years 0.3
Extreme 0.3
14.95
Manager TitleAgeSince
Chief Executive Officer 55 2008-07-23
Director of Finance/CFO 62 2024-08-13
President 68 2020-04-27
Director TitleAgeSince
Director/Board Member 77 2011-07-24
Director/Board Member 55 2008-12-31
Director/Board Member 65 2014-11-12
Date Insider Type Main position Quantity % Market Cap. Importance
11/18/25 Free

Chief Executive Officer

100,000 0.1593%
8/8/25 Free

Chief Financial Officer

161,500 0.2579%
8/8/25 Free

Chief Executive Officer

242,000 0.3865%
Change 5-day change 1-year change 3-year change Capi.($)
+13.55%+8.02%-59.32%-84.65% 21.24M
+1.34%-3.12%+23.51%+9.21% 222B
+1.44%-2.81%+1.99%-20.96% 145B
+0.71%+0.01%-21.43%+19.80% 130B
+0.60%-2.99%-54.15%-9.79% 69.68B
+0.09%-0.06%+11.65%+18.91% 52.3B
+0.41%-0.60%-17.27%-13.84% 50.71B
+0.97%-2.18%+20.48%+24.18% 42.28B
+1.57%-0.54%+36.58%+46.68% 39.87B
-0.21%-2.42%-15.90%+45.03% 33.37B
Average +2.15%-1.59%-7.39%+3.46% 78.62B
Weighted average by Cap. +1.07%-1.58%+0.59%+7.08%

Financials

2026 *2027 *
Net sales 38.88M 33.56M 31.61M 28.84M 53.83M 3.69B 54.27M 374M 145M 1.88B 146M 143M 6.18B 44.16M 38.12M 35.9M 32.76M 61.14M 4.19B 61.65M 425M 165M 2.13B 166M 162M 7.01B
Net income -13.91M -12.01M -11.31M -10.32M -19.26M -1.32B -19.42M -134M -51.93M -672M -52.23M -51.09M -2.21B -2.77M -2.39M -2.25M -2.06M -3.84M -263M -3.87M -26.69M -10.35M -134M -10.41M -10.18M -440M
Net Debt - -
Logo Cytosorbents Corporation
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Employees
129
Date Price Change Volume
26-09-02 US$0.3838 +13.55% 5,626,242
26-09-01 US$0.3380 -0.88% 62,800
26-08-31 US$0.3410 +1.61% 111,597
26-08-28 US$0.3356 -1.41% 113,684
26-08-27 US$0.3404 -5.44% 108,592
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.3380USD
Average target price
2.375USD
Spread / Average Target
+602.66%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CTSO Stock